iQone Healthcare supports Early Access and Named Patient Programs for several of its products in oncology, hematology and rare diseases.

This type of program allows Doctors to offer treatment options that cannot be made available in specific countries and require special authorisations.

 

For more information on this topic please get in touch with one of our national representatives, with Clinigen or via e-mail

CONTACTS PER COUNTRY

If a particular medical need requires that a patient joins our Early Managed Access Program and gains access to belinostat, iQone Healthcare Group will speedily and diligently handle your request and all associated administrative demands.

Please contact us as follows:

1- by email in our contact page,

2- by telephone or fax as given in the table below.

Contacts per Country.
(Clinigen contact numbers):

 

Country Telephone Number Hours of Operation and Time Zone Fax Number
UK / international +44 1283 494 340 9am-5pm (GMT) +44 1283 494 341
Benelux 065 250 307 9am-6pm (CET) +44 1283 494 341
France +33 4 81 68 23 30 9am-6pm (CET) +33 4 81 68 23 31
Germany 069 2222 3413 9am-6pm (CET) 0800 589 2457
Italy 800 977 669 9am-6pm (CET) 800 977 686
Spain 800 600 217 9am-6pm (CET) 800 600 218

 

3- through one of our Medical Science Liaisons (MSL) in the list below:

Country Telephone Number E-mail
UK +33 6 04 65 22 15 nathalie.caizergues@iqone-healthcare.com
Benelux, France, Switzerland (Romandy) +33 6 04 65 22 15 nathalie.caizergues@iqone-healthcare.com
Austria, Germany, Switzerland +49 173 3434236 ulrike.kosub@iqone-healthcare.com
Italy +39 34 28 58 67 42 giuseppe.carmassi@iqone-healthcare.com
Spain +34 661 491 834 francois.riva@iqone-healthcare.com
Scandinavia +33 6 04 65 22 15 nathalie.caizergues@iqone-healthcare.com

 

The eligibility criteria to join our patient program are:

  • Diagnosis of relapsed or refractory peripheral T-cell lymphoma (r/r PTCL).
  • Absolute neutrophil count (ANC) should be greater than or equal to 1.0 x 109/L and the platelet count should be greater than or equal to 50 x 109/L.
  • No active infection.
  • No moderate or severe hepatic impairment (defined as total bilirubin >1.5 x upper limit of normal [ULN]).
  • No renal impairment (defined as Creatinine Clearance ≤ 39 mL/min).
  • No prolongation of QT/QTc interval > 450 msec.
  • No concomitant administration of medication that may cause prolonged QTc time.
  • No concomitant administration of strong inhibitor of UGT1A1.
  • No pregnancy detected.
  • No nursing infants.